Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDA-1102 in Actinic Keratosis
NCT02844777Phase 2Completed
- Sponsor
- Vidac Pharma
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tuvatexib in actinic keratosis (AK), sponsored by Vidac Pharma. Started Jul 2016; status: completed.
02
Drugs
tuvatexib
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02844777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844777.